When the patient is the operator

Somewhere in the country this morning, a woman on warfarin pricked her own finger at her kitchen table, dropped a bead of blood onto a strip, read a number off a small screen, and adjusted her dose. She has done this for years. Her anticoagulation service trained her, checks her, and reviews her results. If her number drifts, someone who understands it will notice. This is one of the oldest and safest examples of a patient acting as their own laboratory operator, and it works because a whole quiet apparatus of governance sits behind it.

Now picture a different scene from the same morning. A man discharged onto a virtual ward the previous evening straps on a pulse oximeter, taps through an app, and uploads a set of readings before his tea goes cold. A few streets away, a woman who bought a bowel cancer screening kit online reads two faint lines, decides they are probably nothing, and puts the box in the recycling. Both of these people are now operators of diagnostic tests. Neither has been trained the way our profession trains an operator. Neither is running quality control. And in at least one of those cases, nobody is guaranteed to see the result.

Here is the thesis, stated plainly. Our governance frameworks for point of care testing quietly assume a trained professional is holding the device. Competency assessment, quality control, adherence to the instructions for use, escalation of abnormal results: every one of those pillars was designed around a member of staff. Home diagnostics, hospital at home and direct to consumer testing move the operator role onto the patient, and they will scale faster than our governance unless we deliberately redesign it. Done well, this is the biggest opportunity in decentralised testing for a generation. Done carelessly, it is a slow leak of clinical risk into people's homes.

The model that already works, and why

Start with what goes right, because it tells us what safety actually requires. Patient self-testing and self-management of the international normalised ratio has a long track record. Where it is done properly, patients on long term anticoagulation are trained to use the device, assessed for competency, and reviewed by a clinical service that owns their care. The evidence base built up over years is reassuring: supported self-testing can be safe and effective.

It is worth being precise about why. INR self-testing did not succeed because the device is foolproof or because patients are unusually diligent. It succeeded because the pathway around the device is complete. Someone selects suitable patients. Someone trains them and signs them off. Someone reviews the numbers and intervenes when they wander. The patient holds the device, but the clinical service still holds the accountability. The operator changed; the governance did not disappear, it was rebuilt around the home.

That distinction is the entire argument of this piece. The hazard is not that patients hold devices. The hazard is assuming that because a device is now portable, cheap and easy, the governance can be thin.

The accountability chain, and where it snaps

In the laboratory, and in well run hospital point of care programmes, accountability is unbroken. A named committee owns the service. A coordinator owns competency and quality. Manufacturers, procurement, clinical leads and operators each hold a defined link. When something fails, you can trace it back along the chain to a person and a process.

Home and remote testing stretches that chain across the front door, and at exactly the point where it crosses the threshold, the traditional owner of quality disappears.

Consider each pillar of point of care governance and ask a simple question: who owns it when the patient is the operator?

• Competency. In a hospital we assess operators, record it, and re-verify it. Who trains the patient at home, who assesses that they can actually do it, and who notices when their technique drifts a year later?
• Quality control. A ward glucose meter runs internal QC and sits in an EQA scheme. A self-test kit typically has none of that. There is no daily control, no Levey-Jennings chart, no external comparison. The only quality signal is the result itself, and by then it has already been believed.
• Adherence to the instructions for use. Professionals are held to the manufacturer's method: sample volume, timing, storage, expiry. At home, a strip may have been left on a sunny windowsill, the reading taken at ninety seconds instead of thirty, the finger squeezed too hard. The device performs to specification; the test does not.
• Result escalation. On a ward, an abnormal result triggers a response by design. At home, an abnormal result triggers whatever the patient decides to do with it, which may be nothing, or panic, or a search engine.

None of these pillars is impossible to rebuild for the home. But none of them rebuilds itself. Left to default, the patient-operator node in that chain is a link with no keeper.

The hazard is not that patients hold devices. The hazard is assuming that because a device is now portable and easy, the governance can be thin.

The new wave, and how it stretches the model

The reason this matters now is scale and speed. Virtual wards and hospital at home are an expanding part of NHS delivery, moving acute-level monitoring into people's bedrooms. Remote monitoring of long term conditions is following. And a large and growing direct to consumer market sells finger-prick and swab tests straight to the public, outside any clinical relationship at all.

Each of these stretches the INR model in a different direction, and it is worth separating them because the governance answers differ.

Hospital at home and virtual wards

Here the patient is inside a clinical pathway, which is the good news. There is a responsible team, a record, and an escalation route in principle. The stretch is operational: the team may be monitoring dozens of patients using devices they did not physically hand over, training delivered in a rushed discharge, and readings arriving through consumer-grade kit. The governance question is whether the same rigour we would demand of a ward glucose meter, verification, competency, a plan for questionable results, has genuinely followed the patient home, or whether it was quietly left at the hospital door.

Remote monitoring of long term conditions

This is the closest cousin to INR self-management, and the place the model most naturally extends. The ingredients for safety are known: selection, training, connected results, review. The risk is dilution. As programmes scale from hundreds of motivated, well-supported patients to tens of thousands, the temptation is to keep the device and drop the wrap-around, because the wrap-around is the expensive part. That is precisely the part that made the original safe.

Direct to consumer testing

This is the sharpest edge, because there may be no clinical relationship at all. In the UK, in-vitro diagnostic devices intended for self-testing by lay users are subject to specific regulatory requirements and marking, and the MHRA oversees medical devices. That regulation is real and it matters: a self-test device must be designed and validated for a lay user, with instructions a non-professional can follow and, for many products, evidence that lay users can actually get the right answer. But regulation of the device is not governance of the pathway. A kit can be entirely compliant and still be used at the wrong time, read incorrectly, or produce a result that reaches no clinician and changes no decision, or changes the wrong one.

The connective tissue safety actually requires

If the operator has moved, the governance has to move with them. It does not vanish; it changes shape. The useful way to think about it is a loop, because a one-way test is where the danger lives.

Every safe example of patient-as-operator I can think of closes that loop. Every worrying one leaves it open. The single most important design decision, more important than the device, is whether an abnormal result is guaranteed to reach a clinician and be acted upon, or merely able to. Those are not the same thing, and the gap between them is where harm accumulates.

Closing the loop has practical requirements. The result needs to be connected, not stranded on a screen the patient may misread and forget. Escalation needs to be defined in advance, with a named recipient and a timescale, not improvised after a frightening number appears. And the patient needs feedback, so that testing feels like part of their care rather than homework they perform into a void.

Design around the pathway, not the device

The mistake I see coming, and in places already here, is to govern the device and forget the pathway. Vendors will tell you a home device is accurate, and it may well be. Accuracy of the analyser was never the hard part. The hard part is everything the laboratory used to do around it, and that responsibility has not been abolished by moving the test into a home. It has been transferred, mostly to people who have not been told they now hold it.

So the governing question for any home or remote testing programme is not "is the device good?" It is "who owns quality now, and can they prove the loop closes?" If a service cannot answer that in a sentence, it does not have a testing programme, it has a testing product, and the difference is measured in patient safety.

This reframing also protects the opportunity. Supported self-testing is genuinely good medicine. It gives patients agency, catches problems earlier, and takes pressure off stretched services. None of the caution above is an argument against home testing. It is an argument for doing it the way the anticoagulation services quietly proved works: train the operator, connect the result, define the escalation, keep the clinical ownership.

What this means for your service

If you commission, run or advise on any programme that puts a testing device into a patient's hands, treat the patient as an operator you are responsible for, and build accordingly.

• Name the owner of quality. Before the first kit ships, decide who owns competency, result review and escalation for patient-operators. If the answer is "the patient", you have not designed a service.
• Train and assess, do not just instruct. A leaflet is not competency. Build in a supported first use, a way to confirm the patient can perform the test, and a light-touch way to re-check technique over time.
• Replace missing quality control with something. Home kits rarely run QC. Compensate with device selection validated for lay use, periodic comparison against a laboratory or professional test where the stakes justify it, and clear expiry and storage guidance patients can actually follow.
• Engineer the escalation. Decide in advance what happens to an abnormal result, who receives it, in what timescale, and how the patient is told. Guaranteed, not possible.
• Connect the result. A number the patient reads and forgets is a hazard. A number that reaches the record and a clinician is care. Close the loop by design.
• Write it into your risk assessment and your assessment prep. Under a single quality management system, testing outside the laboratory's walls is still the laboratory's business. Assessors will increasingly expect to see home and remote testing governed, not ignored.

Our consultancy helps services design this governance around the pathway before a programme scales, and our training, including the POCT fundamentals course, builds the quality thinking that transfers directly to the home setting. If you want to understand what a single well-governed analyte pathway looks like, the long track record of INR self-testing is the case study worth studying, and the wider analyte library shows how differently the stakes sit across tests.

The link with no keeper

Home testing is coming whether our governance is ready or not, and mostly it should come, because supported self-testing at its best is patient care done well. But the woman at her kitchen table is safe not because she owns a good device. She is safe because a service still owns her. The task in front of us is to make sure that as the operator role moves through millions of front doors, the ownership of quality goes with it, and does not quietly stay behind in a building the patient will never visit again.